Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Canopy Growth (CGC) Stock Price & Analysis

11,350 Followers

CGC Stock Chart & Stats

$0.68-$0.08(-10.12%)
At close: 4:00 PM EST
$0.7$0.8$0.9$1Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$0.67 - $0.76
52-Week Range
$0.64 - $2.38
Previous Close
$0.75
Volume
N/A
Average Volume (3M)
2.41M
Market Cap
$333.83M
Enterprise Value
$518.37M
Total Cash (Recent Filing)
$336.63M
Total Debt (Recent Filing)
$277.33M
Price to Earnings (P/E)
―
Beta
1.39
Next Earnings
Feb 05, 2027 (Est.)
EPS Estimate
-0.02
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin Expansion

Broad-based revenue growth alongside a substantial margin improvement indicates that operating initiatives are translating into better economics. If sustained, higher gross margin can support reinvestment, reduce dependence on external funding, and improve the path toward durable profitability.

Improving Canadian Market Position

Gaining Canadian adult-use share while growing revenue suggests stronger brand execution in a competitive regulated market. Leadership in premium flower, infused pre-rolls, and softgels can support product mix, customer retention, and more resilient revenue over the next several quarters.

EU-GMP Certification

EU-GMP certification expands the facility’s ability to support regulated European medical cannabis channels and strengthens Canopy’s compliance credentials. This can improve access to international markets, support future shipments, and make the company’s production platform more strategically useful.

Bears Say

Persistent Unprofitability

Despite the recent operating improvement, Canopy remains deeply unprofitable and its multi-year earnings record is volatile. Continued losses weaken internal capital formation, increase execution pressure, and mean that revenue growth has not yet translated into a dependable earnings model.

Ongoing Cash Burn

Negative operating and free cash flow show that the business is still consuming cash rather than funding its operations internally. Until profitability improves, ongoing cash usage can constrain investment choices and increase reliance on available balance-sheet resources or financing.

Medical Reimbursement Pressure

The reimbursement reduction directly lowers order values in an important medical channel and creates a structural margin headwind. Canopy’s mitigation efforts may help, but sustained pricing pressure could limit medical growth economics and offset gains from patient and revenue expansion.

Canopy Growth News

CGC FAQ

What was Canopy Growth’s price range in the past 12 months?
Canopy Growth lowest stock price was $0.64 and its highest was $2.38 in the past 12 months.
What is Canopy Growth’s market cap?
Canopy Growth’s market cap is $333.83M.
When is Canopy Growth’s upcoming earnings report date?
Canopy Growth’s next earnings report is estimated for Feb 05, 2027 (not yet confirmed), which is in 91 days.
How were Canopy Growth’s earnings last quarter?
Canopy Growth released its earnings results on Nov 06, 2026. The company reported -$0.071 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.044.
Is Canopy Growth overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Canopy Growth pay dividends?
Canopy Growth does not currently pay dividends.
What is Canopy Growth’s EPS estimate?
Canopy Growth’s EPS estimate is -0.02.
How many shares outstanding does Canopy Growth have?
Canopy Growth has 419,568,000 shares outstanding.
What happened to Canopy Growth’s price movement after its last earnings report?
Canopy Growth reported an EPS of -$0.071 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went up 4.077%.
Which hedge fund is a major shareholder of Canopy Growth?
Currently, no hedge funds are holding shares in CGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology